EA201592287A1 - Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения - Google Patents

Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения

Info

Publication number
EA201592287A1
EA201592287A1 EA201592287A EA201592287A EA201592287A1 EA 201592287 A1 EA201592287 A1 EA 201592287A1 EA 201592287 A EA201592287 A EA 201592287A EA 201592287 A EA201592287 A EA 201592287A EA 201592287 A1 EA201592287 A1 EA 201592287A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
carbazolkarboxamide
connections
disclosed
substituted tetrahydrocarbazole
Prior art date
Application number
EA201592287A
Other languages
English (en)
Other versions
EA026729B1 (ru
Inventor
Джозеф А. Тино
Анураг С. Сривастава
Соо Сун Ко
Майкл А. Галелла
Чарльз М. Лангевайн
Джордж В. Делукка
Цинцзе Лю
Дуглас Г. Батт
Скотт Хантер Уотерсон
Цин Ши
Мира Бодуа Бертран
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201592287A1 publication Critical patent/EA201592287A1/ru
Publication of EA026729B1 publication Critical patent/EA026729B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Раскрыты соединения формулы (I)где: обе пунктирные линии отображают либо две одинарные, либо две двойные связи;Q представляет собойилиRпредставляет собой F, Cl, -CN или -СН; Rпредставляет собой С1 или -СН; Rпредставляет собой -С(СН)ОН или -СНСНОН; Rпредставляет собой Н или -СН; каждый Rнезависимо представляет собой F, Cl, -СНи/или -ОСН; и n имеет значения 0, 1 или 2. Также раскрыты способы применения таких соединений в качестве ингибиторов тирозинкиназы Брутона (Btk) и фармацевтических композиций, содержащих такие соединения. Эти соединения являются полезными для лечения, предупреждения или замедления прогрессирования заболеваний или расстройств в различных терапевтических областях, таких как аутоиммунные заболевания и заболевание сосудов.
EA201592287A 2013-06-25 2014-06-25 Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения EA026729B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839141P 2013-06-25 2013-06-25
PCT/US2014/043978 WO2014210085A1 (en) 2013-06-25 2014-06-25 Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201592287A1 true EA201592287A1 (ru) 2016-06-30
EA026729B1 EA026729B1 (ru) 2017-05-31

Family

ID=51210830

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592287A EA026729B1 (ru) 2013-06-25 2014-06-25 Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения

Country Status (31)

Country Link
US (6) US9334290B2 (ru)
EP (1) EP3013814B1 (ru)
JP (1) JP6353529B2 (ru)
KR (1) KR102346508B1 (ru)
CN (1) CN105358546B (ru)
AR (1) AR096721A1 (ru)
AU (1) AU2014302548B2 (ru)
BR (1) BR112015030723A8 (ru)
CA (1) CA2916500A1 (ru)
CL (1) CL2015003635A1 (ru)
CY (1) CY1119371T1 (ru)
DK (1) DK3013814T3 (ru)
EA (1) EA026729B1 (ru)
ES (1) ES2636652T3 (ru)
HK (1) HK1223359A1 (ru)
HR (1) HRP20171031T1 (ru)
HU (1) HUE034460T2 (ru)
IL (1) IL243296B (ru)
LT (1) LT3013814T (ru)
MA (1) MA38648B1 (ru)
MY (1) MY176631A (ru)
PE (1) PE20160519A1 (ru)
PH (1) PH12015502630A1 (ru)
PL (1) PL3013814T3 (ru)
PT (1) PT3013814T (ru)
RS (1) RS56371B1 (ru)
SI (1) SI3013814T1 (ru)
TN (1) TN2015000529A1 (ru)
TW (1) TWI648272B (ru)
UY (1) UY35625A (ru)
WO (1) WO2014210085A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102345381B1 (ko) 2013-06-25 2021-12-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
WO2016065222A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
DK3209656T3 (da) 2014-10-24 2020-07-13 Bristol Myers Squibb Co Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere
AU2015335703B2 (en) * 2014-10-24 2020-05-21 Bristol-Myers Squibb Company Carbazole derivatives
AU2017290142A1 (en) 2016-07-01 2019-01-17 Brio Device Llc Intubation stylet with video feed
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
WO2018118830A1 (en) * 2016-12-20 2018-06-28 Bristol-Myers Squibb Company Process for preparing tetrahydrocarbazole carboxamide compound
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2023156311A1 (en) * 2022-02-15 2023-08-24 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
BRPI0517211B8 (pt) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa composto, composição farmacêutica e seu uso.
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
JP2009508872A (ja) * 2005-09-16 2009-03-05 セレネックス， インコーポレイテッド カルバゾール誘導体
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006316322B2 (en) 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
SG174810A1 (en) 2006-09-11 2011-10-28 Matrix Lab Ltd Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
JP5489296B2 (ja) 2007-12-13 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2794211A1 (en) 2010-03-26 2011-09-29 Wolfgang Staehle Benzonaphthyridinamines as autotaxin inhibitors
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
CA2834077A1 (en) 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy

Also Published As

Publication number Publication date
US20190382416A1 (en) 2019-12-19
AU2014302548A1 (en) 2016-02-11
MA38648A1 (fr) 2017-09-29
JP6353529B2 (ja) 2018-07-04
AU2014302548B2 (en) 2018-05-10
TW201536774A (zh) 2015-10-01
PE20160519A1 (es) 2016-05-21
ES2636652T3 (es) 2017-10-06
US10106559B2 (en) 2018-10-23
US20160194338A1 (en) 2016-07-07
KR102346508B1 (ko) 2022-01-03
MY176631A (en) 2020-08-19
CA2916500A1 (en) 2014-12-31
PL3013814T3 (pl) 2017-11-30
CN105358546B (zh) 2017-10-31
EA026729B1 (ru) 2017-05-31
BR112015030723A2 (pt) 2017-07-25
US20140378475A1 (en) 2014-12-25
IL243296B (en) 2018-05-31
RS56371B1 (sr) 2017-12-29
PH12015502630A1 (en) 2016-03-07
AR096721A1 (es) 2016-01-27
MA38648B1 (fr) 2018-06-29
EP3013814A1 (en) 2016-05-04
UY35625A (es) 2014-12-31
KR20160022889A (ko) 2016-03-02
CN105358546A (zh) 2016-02-24
TN2015000529A1 (en) 2017-04-06
HUE034460T2 (en) 2018-02-28
US20170283438A1 (en) 2017-10-05
WO2014210085A9 (en) 2015-12-23
US9334290B2 (en) 2016-05-10
US10435415B2 (en) 2019-10-08
BR112015030723A8 (pt) 2020-01-07
HRP20171031T1 (hr) 2017-10-06
US20180079758A1 (en) 2018-03-22
US20190023719A1 (en) 2019-01-24
LT3013814T (lt) 2017-08-10
TWI648272B (zh) 2019-01-21
JP2016523907A (ja) 2016-08-12
EP3013814B1 (en) 2017-06-14
US9850258B2 (en) 2017-12-26
WO2014210085A1 (en) 2014-12-31
PT3013814T (pt) 2017-08-10
DK3013814T3 (en) 2017-09-25
HK1223359A1 (zh) 2017-07-28
CL2015003635A1 (es) 2016-07-29
SI3013814T1 (sl) 2017-08-31
CY1119371T1 (el) 2018-02-14

Similar Documents

Publication Publication Date Title
EA201592287A1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201690012A1 (ru) Карбазолкарбоксамидные соединения
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201891553A1 (ru) Ингибиторы syk
EA201690094A1 (ru) Ингибиторы syk
EA201690752A1 (ru) Ингибиторы g12c kras
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
EA201790088A1 (ru) Ингибиторы syk
EA201790745A1 (ru) Трициклические соединения
EA201790870A1 (ru) Трициклические атропоизомерные соединения
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-
EA202191103A1 (ru) Терапевтические соединения
EA202190787A1 (ru) Пиридазиноны и способы их применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU